A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjogren's Syndrome
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Seletalisib (Primary)
- Indications Sjogren's syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors UCB
- 17 Oct 2017 This trial has been Discontinued in Greece.
- 09 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Jul 2018.
- 09 Mar 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2018.